Safety Profile of Iloperidone
- 1 April 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 28 (2), S12-S19
- https://doi.org/10.1097/jcp.0b013e3181694f5a
Abstract
Iloperidone, a mixed D2/5-HT2 antagonist, is currently in clinical development for the treatment of schizophrenia. This article assesses the short-term safety of iloperidone using a pooled analysis of 3 phase 2, short-term acute schizophrenia studies conducted between 1998 and 2002 (N = 1943). Patients exposed to 3 dose ranges of iloperidone, another antipsychotic, or placebo were compared on rates of serious adverse events (SAEs), adverse events (AEs), extrapyramidal symptoms, akathisia, prolactin, weight and metabolic parameters, QTc, and other standard safety parameters. The most common treatment-related AEs observed with iloperidone were dizziness, headache, dry mouth, nausea, and insomnia. Discontinuation due to AEs was 4.8% for iloperidone, 7.6% for haloperidol, 6.2% for risperidone, and 4.8% for placebo. Iloperidone groups showed better overall performance on the Extrapyramidal Symptom Rating Scale and Barnes Akathisia Scale than risperidone or haloperidol groups. Patients taking iloperidone experienced a mild weight increase (range, 1.5-2.1 kg) similar to that of risperidone (1.5 kg), whereas those on haloperidol and placebo showed mean weight loss (-0.1 kg and -0.3 kg, respectively). QTc interval significantly increased across all iloperidone groups (least squares mean change from baseline to end point, 2.9-9.1 msec) and for haloperidol (5.0 msec). No significant QTc changes occurred in the risperidone or placebo groups. Iloperidone was associated with no change from baseline in total cholesterol, mild elevation in serum glucose, and slight decrease in triglycerides. Prolactin levels decreased with iloperidone and increased significantly with risperidone and haloperidol. These short-term trials suggest that iloperidone has a reassuring safety profile in many of the areas that are of potential concern, including relatively low dropout rates because of AEs, low extrapyramidal symptoms, akathisia, and prolactin elevation, and a modest short-term effect on weight gain.Keywords
This publication has 24 references indexed in Scilit:
- Ziprasidone for Schizophrenia and Bipolar Disorder: A Review of the Clinical TrialsCNS Drug Reviews, 2007
- A review of atypical antipsychotic drugs versus conventional medication in schizophreniaExpert Opinion on Pharmacotherapy, 2006
- Manual for the Extrapyramidal Symptom Rating Scale (ESRS)Schizophrenia Research, 2005
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- Functional characterization of the novel antipsychotic iloperidone at human D2, D3, α2C, 5-HT6, and 5-HT1A receptorsLife Sciences, 2003
- Extended Radioligand Binding Profile of Iloperidone A Broad Spectrum Dopamine/Serotonin/Norepinephrine Receptor Antagonist for the Management of Psychotic DisordersNeuropsychopharmacology, 2001
- Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden DeathAmerican Journal of Psychiatry, 2001
- Many ThanksBritish Journal of Psychology, 2001
- Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compoundsLife Sciences, 2000
- Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei HerzkrankenActa Medica Scandinavica, 1920